Skip to main content
C

CELLUMED CO., LTD. — Investor Relations & Filings

Ticker · 049180 ISIN · KR7049180003 KO Manufacturing
Open in API
Filings indexed 396 across all filing types
Latest filing 2020-09-25 Capital/Financing Update
Country KR South Korea
Listing KO 049180

About CELLUMED CO., LTD.

http://www.clnzyme.co.kr/

CELLUMED CO., LTD. is a biotechnology company specializing in the development and manufacturing of medical devices, tissue grafts, and advanced biologics. The company operates as a human tissue bank, producing and supplying a variety of bone graft materials, including allografts and xenografts, for transplantation. Its medical device portfolio features orthopedic implants, with a key product being an artificial knee joint system. In the biologics sector, Cellumed develops growth factors and provides specialized enzymes, such as CLnZyme, which are utilized in the research, development, and production of RNA-based vaccines and therapeutics.

Recent filings

Filing Released Lang Actions
단기차입금감소결정(자율공시)
Capital/Financing Update Classification · 1% confidence The document is a regulatory filing from the company Cellumed regarding a decision to reduce short-term debt. It details the amount of the reduction, the impact on the company's financial structure, and the board's resolution date. This falls under the category of financing and capital structure updates.
2020-09-25 Korean
단기차입금감소결정(자율공시)
Capital/Financing Update Classification · 1% confidence The document is a regulatory filing from Cellumed regarding a decision to reduce short-term debt. It details the amount of reduction, the impact on equity, the reason for the change (financial cost reduction), and the board resolution date. This falls under financing activities and capital structure changes, which is best categorized as CAP (Capital/Financing Update).
2020-09-02 Korean
반기보고서 (2020.06)
Interim / Quarterly Report Classification · 1% confidence The document is a '반기보고서' (Semi-annual Report) for the company 'Cellumed'. It contains detailed corporate information, history, management changes, and capital structure updates, which are characteristic of a comprehensive interim financial report. It is not a short announcement or a certification letter, but a full report covering the company's operations and financial status for the period, fitting the definition of an Interim/Quarterly Report (IR). H1 2020
2020-08-24 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership, specifically identifying the reporting entity (Inscobee) and its special relations (directors/executives) following a third-party capital increase. This falls under the category of Major Shareholding Notification.
2020-08-20 Korean
증권발행결과(자율공시)(제3자배정 유상증자)
Share Issue/Capital Change Classification · 1% confidence The document is a formal announcement regarding the results of a third-party capital increase (share issuance) by Cellumed. It details the number of shares issued, the total amount raised, and the payment date. This falls under the category of share issuance and capital changes.
2020-08-18 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (DART system) used when an entity or individual crosses a 5% ownership threshold or experiences significant changes in their holdings. This falls under the 'Major Shareholding Notification' category.
2020-08-18 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.